Terms: = Lymphoma AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Treatment
215 results:
1. Efficacy and Safety in Early application of Ruxolinitib for high-risk: Acute lymphoblastic leukemia to prevent GVHD and recurrence after allogeneic hematopoietic stem cell transplantation.
Cheng Q; Tang Y; Liu F; Li X; Fang D
Transpl Immunol; 2024 Apr; 83():101978. PubMed ID: 38302005
[TBL] [Abstract] [Full Text] [Related]
2. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
3. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation.
Williams LS; Williams KM; Gillis N; Bolton K; Damm F; Deuitch NT; Farhadfar N; Gergis U; Keel SB; Michelis FV; Panch SR; Porter CC; Sucheston-Campbell L; Tamari R; Stefanski HE; Godley LA; Lai C
Transplant Cell Ther; 2024 Mar; 30(3):255-267. PubMed ID: 37913908
[TBL] [Abstract] [Full Text] [Related]
4. Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach.
Le K; Vollenweider J; Han J; Staudinger N; Stenson M; Bayraktar L; Wellik LE; Maurer MJ; McPhail ED; Witzig TE; Gupta M
Hematol Oncol; 2024 Jan; 42(1):e3233. PubMed ID: 37876297
[TBL] [Abstract] [Full Text] [Related]
5. Cross-Study Comparisons of jak2 Inhibitors in Myelofibrosis: Risks and Recommendations.
Mascarenhas J; Mesa R
Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):714-718. PubMed ID: 37357030
[TBL] [Abstract] [Full Text] [Related]
6. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in
Senapati J; Jabbour E; Konopleva M; Short NJ; Tang G; Daver N; Kebriaei P; Kadia T; Pemmaraju N; Takahashi K; DiNardo C; Sasaki K; Borthakur G; Thakral B; Kanagal-Shamanna R; Patel K; Ravandi F; Roberts K; Mullighan C; Kantarjian H; Jain N
JCO Precis Oncol; 2023 May; 7():e2200707. PubMed ID: 37196217
[TBL] [Abstract] [Full Text] [Related]
7. 'Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting.
Gupta DG; Varma N; Sreedharanunni S; Abdulkadir SA; Naseem S; Sachdeva MUS; Binota J; Bose P; Malhotra P; Khadwal A; Varma S
Br J Cancer; 2023 Jul; 129(1):143-152. PubMed ID: 37156894
[TBL] [Abstract] [Full Text] [Related]
8. Cardiovascular Toxicities Associated with Anaplastic lymphoma Kinase Inhibitors: A Disproportionality Analysis of the WHO Pharmacovigilance Database (VigiBase).
Niimura T; Miyata K; Hamano H; Nounin Y; Unten H; Yoshino M; Mitsuboshi S; Aizawa F; Yagi K; Koyama T; Goda M; Kanda Y; Izawa-Ishizawa Y; Zamami Y; Ishizawa K
Drug Saf; 2023 Jun; 46(6):545-552. PubMed ID: 37106270
[TBL] [Abstract] [Full Text] [Related]
9. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract] [Full Text] [Related]
10. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with jak2 rearrangement-A 10-case study and literature review.
Zhang L; Shah B; Zhang Y; Tashkandi H; Xiao W; Fernandez-Pol S; Vergara-Lluri M; Hussaini M; Song J; Lancet J; Moscinski L; Yun S; Lu CM; Medeiros LJ; Tang G
Hum Pathol; 2023 Jun; 136():1-15. PubMed ID: 36958463
[TBL] [Abstract] [Full Text] [Related]
11. Distinctive Attributes of Indian Patients With Classical BCR::ABL1 Negative Myeloproliferative Neoplasms: Unified Clinical and Laboratory Data.
Singh S; Singh J; Mehta A; Sharma R; Joshi K; Jain K; Paul D; Oberoi G; Jindal N; Dhillon B; Narang V
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):360-369.e1. PubMed ID: 36849307
[TBL] [Abstract] [Full Text] [Related]
12. SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis.
Chifotides HT; Masarova L; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2023 Apr; 23(4):219-231. PubMed ID: 36797153
[TBL] [Abstract] [Full Text] [Related]
13. [Lymphoplasmacytic lymphoma accompanied by severe myelofibrosis].
Takarada A; Momose H; Kurita N; Matsuoka R; Nakamura N; Sakamoto T; Kato T; Hattori K; Suehara Y; Yokoyama Y; Nishikii H; Maruyama Y; Obara N; Chiba S; Sakata-Yanagimoto M
Rinsho Ketsueki; 2023; 64(1):54-59. PubMed ID: 36775308
[TBL] [Abstract] [Full Text] [Related]
14. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Zhang Y; Nguyen L; Lu CM; Wang E; Lauw MIS; Ball S; Dong N; Moscinski L; Chan O; Yun S; Sallman D; Sokol L; Shah B; Knepper T; Lancet J; Komrokji R; Padron E; Kuykendall A; Zhang L
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):e150-e163. PubMed ID: 36624015
[TBL] [Abstract] [Full Text] [Related]
15. SOHO State of the Art Updates and Next Questions | Polycythemia Vera: Is It Time to Rethink treatment?
Mora B; Passamonti F
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):79-85. PubMed ID: 36566109
[TBL] [Abstract] [Full Text] [Related]
16. The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell lymphoma.
Li J; Yu H; Wang X; Ye Y; Fang W; Ding N; Mi L; Ping L; Wang X; Song Y; Zhu J
Cancer Control; 2022; 29():10732748221143881. PubMed ID: 36519740
[TBL] [Abstract] [Full Text] [Related]
17. Carvedilol exhibits anti-acute T lymphoblastic leukemia effect in vitro and in vivo via inhibiting β-ARs signaling pathway.
Xu Y; Li J; Luo Y; Ma J; Huang P; Chen Y; He Z
Biochem Biophys Res Commun; 2023 Jan; 639():150-160. PubMed ID: 36495764
[TBL] [Abstract] [Full Text] [Related]
18. [Cell Cycle Arrest and Apoptosis Induced by Atovaquone in Non-Hodgkin's lymphoma Raji Cells].
Chen CY; Shen X; Xing S; Zhang XW; Jiang G; Yu ZY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1746-1751. PubMed ID: 36476898
[TBL] [Abstract] [Full Text] [Related]
19. [Effect of HDAC Inhibitor Chidamide on PD-L1 Expression in Peripheral T-Cell lymphoma].
Yan MM; Li ZX; Chen C; Zhang W; Zhou DB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1741-1745. PubMed ID: 36476897
[TBL] [Abstract] [Full Text] [Related]
20. JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options.
Stein BL
Leuk Lymphoma; 2023 Feb; 64(2):292-299. PubMed ID: 36301740
[TBL] [Abstract] [Full Text] [Related]
[Next]